☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - March 2018

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Lacosamide (Vimpat®) has been rejected for use as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy. The manufacturer failed to make a submission.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - March 2018' by emailShare 'SMC Update - March 2018' on FacebookShare 'SMC Update - March 2018' on TwitterShare 'SMC Update - March 2018' on LinkedInShare 'SMC Update - March 2018' on reddit

atomic-wealth

No Comments to “SMC Update - March 2018”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.

governor
governor
governor
governor